PDS Biotech to be Added to Russell 2000® and Russell 3000® Indexes Effective June 26, 2023
20. Juni 2023 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., June 20, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corp. (NASDAQ: PDSB), a clinical-stage company developing a growing pipeline of targeted immunotherapies for cancer and...
PDS Biotechnology Announces Achievement of Efficacy Threshold in Stage 2 of the VERSATILE-002 Trial Evaluating PDS0101 and KEYTRUDA® in Head and Neck Cancer
14. Juni 2023 08:00 ET
|
PDS Biotechnology Corporation
14 patients in the immune checkpoint inhibitor naïve arm of VERSATILE-002 have experienced either a complete response or partial response on two consecutive scans, thus constituting a confirmed...
PDS Biotechnology Post-ASCO Conference Call Tomorrow, June 6, at 8 a.m. ET
05. Juni 2023 14:52 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with KEYTRUDA® (pembrolizumab) for Head and Neck Cancer Patients
25. Mai 2023 17:00 ET
|
PDS Biotechnology Corporation
Interim data being presented at ASCO 2023 Annual Meeting Demonstrated median progression-free survival (PFS) of 10.4 months Demonstrated 12-month overall survival (OS) rate of 87.1%A disease control...
PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2023 Financial Results
04. Mai 2023 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech to Participate in Cantor’s Future of Oncology Virtual Symposium
29. März 2023 07:30 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted...
PDS Biotech to Participate at the B. Riley Securities 3rd Annual Oncology Conference
13. Januar 2023 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Jan. 13, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Executives to Present an Overview of Oncology and Infectious Disease Programs at the World Vaccine & Immunotherapy Congress
21. November 2022 08:00 ET
|
PDS Biotechnology Corporation
Chief Medical Officer, Dr. Lauren V. Wood, to present on the development of targeted immunotherapies for solid tumors based on the Versamune® platform Dr. Siva Gandhapudi, Director of...
PDS Biotech Reports Third Quarter 2022 Financial Results and Provides Business Update
14. November 2022 07:30 ET
|
PDS Biotechnology Corporation
Announced preliminary PDS0101 efficacy and safety data for Phase 2 clinical studies led by The University of Texas MD Anderson Cancer Center (IMMUNOCERV) and The National Cancer Institute at SITC...
PDS Biotech Announces 100% Clinical Response in Cervical Cancer Patients in Preliminary Data from IMMUNOCERV Phase 2 Clinical Trial
14. November 2022 07:00 ET
|
PDS Biotechnology Corporation
In the trial studying the combination of PDS0101 with standard-of-care chemoradiotherapy: 100% (9/9) showed clinical response (>60% tumor shrinkage at mid-point evaluation)89% (8/9) had no...